Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Hologic Receives Emergency Use Authorization for Second SARS-CoV-2 Test

Hologic Receives Emergency Use Authorization for Second SARS-CoV-2 Test

May 15, 2020
|
staff reporter

NEW YORK ─ Hologic said Friday it has received Emergency Use Authorization from the US Food and Drug Administration for its Aptima SARS-CoV-2 assay to detect the novel coronavirus.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Genomics to Trace, Prevent

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Sense of Scope in San Diego

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Boost to Wolf Diversity

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

Science Papers Present Algorithm to Diagnose Slowly Progressing Diseases, Korean Genome Project

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

  2. FDA Adds At-Home Self-Collection Template to SARS-CoV-2 Emergency Use Authorization Guidance

  3. FDA Releases Reference Panel for Coronavirus Test Developers

  4. Quest Diagnostics Receives FDA Emergency Use Authorization for COVID-19 Self-Collection Test Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.